Shots:

• The companies collaborated to evaluate F-star’s FS120 (tetravalent bispecific Ab targeting CD137 & OX40) + MSD’s Keytruda (anti-PD-1 therapy) in patients with cancer
• The P-I study evaluates the PK & PD of FS120 as monothx. in dose escalation in patients with advanced cancer while MSD will supply Keytruda for a combination arm in the same study. In preclinical studies- FS120 has demonstrated strong additive effects in combination with Keytruda
• F-star is expected to give an update of FS120 monothx. accelerated dose titration cohorts in 2021 and plans to start the Keytruda combination cohorts in H2’22- upon completion of the FS120 monothx. dose escalation

  | Ref: Globenewswire | Image: PR Newswire